Jump to content

Botiacrine

From Wikipedia, the free encyclopedia
Botiacrine
Clinical data
Other namesMo 876; DMA
Identifiers
  • S-[2-(dimethylamino)ethyl] 9,9-dimethylacridine-10-carbothioate
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H24N2OS
Molar mass340.49 g·mol−1
3D model (JSmol)
  • CC1(C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)SCCN(C)C)C
  • InChI=1S/C20H24N2OS/c1-20(2)15-9-5-7-11-17(15)22(18-12-8-6-10-16(18)20)19(23)24-14-13-21(3)4/h5-12H,13-14H2,1-4H3
  • Key:QXRUCDDVUMKOPI-UHFFFAOYSA-N

Botiacrine (INNTooltip International Nonproprietary Name; developmental code name Mo 876) is a drug of the tricyclic family described as an antiparkinsonian agent which was either never marketed or was possibly marketed outside of the United States.[1][2][3][4][5] It was first described in the literature by 1965.[1] The drug is an acridine derivative and is structurally related to the tricyclic antidepressant dimetacrine.[1]

References

[edit]
  1. ^ a b c Elks, J. (2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer US. p. 170. ISBN 978-1-4757-2085-3. Retrieved 20 October 2024.
  2. ^ Negwer, M. (1994). Organic-chemical Drugs and Their Synonyms: (an International Survey). Akad.-Verlag. p. 1768. ISBN 978-3-05-500156-7. Retrieved 20 October 2024.
  3. ^ Unlisted Drugs. Unlisted Drugs Committee of the Pharmaceutical Section, Science-Technology Group, Special Libraries Association. 1977. pp. 112–113. Retrieved 20 October 2024.
  4. ^ "BOTIACRINE". Inxight Drugs. Retrieved 20 October 2024.
  5. ^ Publishing, W.A.W.A. (2013). Pharmaceutical Manufacturing Encyclopedia. Volumes 1-4. William Andrew. pp. 657–658. ISBN 978-0-8155-1856-3. Retrieved 20 October 2024.